Alumis vs Tvardi Therapeutics
ALMS and TVRD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALMS and TVRD compare
Alumis is the larger company, worth 82 times as much as Tvardi Therapeutics ($871M against $10.6M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALMS | TVRD |
|---|---|---|
| Size and price | ||
| Market cap | $871M | $10.6M |
| Share price | $6.73 | $0.793 |
| Change, 1 year | 42.9% | −83.4% |
| Change, 5 years | – | −99.9% |
| Beta (5Y) | −1.18 | 1.10 |
| Employees | 224 | 12 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 118× | – |
| P/B | 1.9× | 1.3× (better) |
| FCF yield | −40.4% | – |
| Profitability | ||
| Operating margin | −6204% | – |
| Net margin | −5933% | – |
| FCF margin | −4755% | – |
| Return on equity | −93.6% (better) | −126% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.74 (better) | 1.87 |
| Altman Z-score | 0.23 (better) | −13.77 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.3% | 16.7% |
| Held by insiders | 30.5% | 15.6% |
| Insider net buying, 12 months | $60.1M | – |
| Short interest, % of float | 11.5% | 2.0% |
Go deeper
- ALMS stock overview
- ALMS income statement
- ALMS valuation and score
- TVRD stock overview
- TVRD income statement
- TVRD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.